ReviewThe oncologist2018
Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey.
Review in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Preoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review.Radiation oncology (London, England) · 2022Pooled it
- Surgical management of urolithiasis - a systematic analysis of available guidelines.BMC urology · 2018Pooled it
- The impact of non-centralised surgical treatment on local recurrence, amputation rate and survival in patients with extremity soft tissue sarcoma.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2026Article
- ASO Practice Guidelines Series: Soft Tissue Sarcoma of the Extremities and Superficial Trunk.Annals of surgical oncology · 2025Review
- Preoperative accelerated hypofractionated radiotherapy (PHYPORT): state of art and potential clinical application.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Review
- Article
- Correlation betweenQuantitative imaging in medicine and surgery · 2023Article
- Article
- The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy.Cancer communications (London, England) · 2022Review
- The role of neoadjuvant radiochemotherapy in the management of localized high-grade soft tissue sarcoma.Radiation oncology (London, England) · 2022Article
- The Feasibility Study of Hypofractionated Radiotherapy with Regional Hyperthermia in Soft Tissue Sarcomas.Cancers · 2021Article
- Article
- Biological reconstruction in the treatment of extremity sarcoma in femur, tibia, and humerus.Medicine · 2020Article
- Multidisciplinary treatment of soft tissue sarcomas: An update.World journal of clinical oncology · 2020Review
- Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS).Journal of cancer research and clinical oncology · 2020Article
- Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine.Therapeutic advances in gastroenterology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe management of localized extremity soft tissue sarcomas (STS) is challenging and the role of pre- and postoperative chemotherapy is unclear and debated among experts. MATERIALS AND
methodsMedical oncology experts of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group were asked to participate in this survey on the use of pre- and postoperative chemotherapy in STS. Experts from 12 centers in Belgium, France, Germany, Great Britain, Italy, Switzerland, and The Netherlands agreed to participate and provided their treatment algorithm. Answers were converted into decision trees based on the objective consensus methodology. The decision trees were used as a basis to identify consensus and discrepancies.
resultsSeveral criteria used for decision-making in extremity STS were identified: chemosensitivity, fitness, grading, location, and size. In addition, resectability and resection status were relevant in the pre- and postoperative setting, respectively. Preoperative chemotherapy is considered in most centers for marginally resectable tumors only. Yet, in some centers, neoadjuvant chemotherapy is used routinely and partially combined with hyperthermia. Although most centers do not recommend postoperative chemotherapy, some offer this treatment on a regular basis. Radiotherapy is an undisputed treatment modality in extremity STS.
conclusionDue to lacking evidence on the utility of pre- and postoperative chemotherapy in localized extremity STS, treatment strategies vary considerably among European experts. The majority recommended neoadjuvant chemotherapy for marginally resectable grade 2-3 tumors; the majority did not recommend postoperative chemotherapy in any setting. IMPLICATIONS FOR PRACTICE: The management of localized extremity soft tissue sarcomas (STS) is challenging and the role of pre- and postoperative chemotherapy is unclear and debated among experts. This study analyzed the decision-making process among 12 European experts on systemic therapy for STS. A wide range of recommendations among experts regarding the use of perioperative chemotherapy was discovered. Discrepancies in the use of decision criteria were also uncovered, including the definition of what constitutes high-risk cancer, which is a basis for many to recommend chemotherapy. Before any standardization is possible, a common use of decision criteria is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.